These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 21916163

  • 1. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor).
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract] [Full Text] [Related]

  • 2. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN, Kasatkin DS, Stepanov IO, Shipova EG, Baranova NS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [Abstract] [Full Text] [Related]

  • 3. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J, So TY.
    Drugs; 2012 Jun 18; 72(9):1195-211. PubMed ID: 22642799
    [Abstract] [Full Text] [Related]

  • 4. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor).
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Jun 18; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV, Dembek C.
    J Manag Care Pharm; 2011 Jun 18; 17(5):377-81. PubMed ID: 21657808
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S, Suppiah V, O'Doherty C.
    Autoimmun Rev; 2014 Feb 18; 13(2):178-86. PubMed ID: 24189284
    [Abstract] [Full Text] [Related]

  • 11. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW.
    Can J Neurol Sci; 2011 May 18; 38(3):429-33. PubMed ID: 21515501
    [Abstract] [Full Text] [Related]

  • 12. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, Foulds P, Mårlind J, Curtius D.
    BMC Neurol; 2011 Nov 10; 11():144. PubMed ID: 22074056
    [Abstract] [Full Text] [Related]

  • 13. Disease modifying treatment in multiple sclerosis.
    Fuller GN, Bone I.
    J Neurol Neurosurg Psychiatry; 2001 Dec 10; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract] [Full Text] [Related]

  • 14. [A possible effect of the immunomodulating therapy with beta-interferons and glatimer acetate on the development of thyroid disease in patients with multiple sclerosis].
    Petrova LV, Boĭkova AN, Batysheva TT, Gusev EI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Dec 10; 111(2 Pt 2):58-67. PubMed ID: 21916158
    [Abstract] [Full Text] [Related]

  • 15. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT, Steffensen LH.
    Ir J Med Sci; 2009 Jun 10; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract] [Full Text] [Related]

  • 16. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review.
    Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JB, Carneiro DS, Carvalho MJ, Claudino R, Comini-Frota ER, Domingues RB, Finkelzstejn A, Gama PD, Giacomo MC, Gomes S, Goncalves MV, Grzesiuk AK, Kaimen-Maciel DR, Mendes MF, Morales NM, Morales RR, Muniz A, Papais-Alvarenga RM, Parolin MK, Ribeiro SB, Ruocco HH, Siquineli F, Tosta ED.
    CNS Drugs; 2013 Nov 10; 27(11):955-61. PubMed ID: 24114585
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S.
    Neurology; 2002 Apr 23; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [Abstract] [Full Text] [Related]

  • 18. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA.
    Arq Neuropsiquiatr; 2000 Sep 23; 58(3A):769-76. PubMed ID: 10973126
    [Abstract] [Full Text] [Related]

  • 19. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR.
    J Manag Care Pharm; 2007 Apr 23; 13(3):287-9. PubMed ID: 17407397
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.